Bank of Nova Scotia Boosts Holdings in Cencora, Inc. $COR

Bank of Nova Scotia raised its position in Cencora, Inc. (NYSE:COR) by 7.7% in the 1st quarter, Holdings Channel.com reports. The fund owned 186,015 shares of the company’s stock after acquiring an additional 13,366 shares during the quarter. Bank of Nova Scotia’s holdings in Cencora were worth $58,435,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora in the 4th quarter worth $25,000. Oakworth Capital Inc. acquired a new position in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the fourth quarter valued at about $27,000. Archer Investment Corp raised its stake in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the last quarter. Finally, Motiv8 Investments LLC acquired a new stake in Cencora in the fourth quarter worth about $29,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Stock Up 1.5%

COR stock opened at $309.67 on Friday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The firm has a 50-day simple moving average of $284.52 and a 200-day simple moving average of $316.47. The stock has a market capitalization of $60.25 billion, a P/E ratio of 23.75, a P/E/G ratio of 1.69 and a beta of 0.58.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the previous year, the firm posted $4.42 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on COR. UBS Group boosted their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating for the company. Citigroup dropped their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company cut their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Finally, Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. Eleven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.